Tout DSpace

Parcourir par sujet "thrombospondin"

Voici les éléments 1-3 de 3

    • Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis 

      Müller T., Alberts R., De Vries E.M.G., Goode E.C., Jiang X., Sampaziotis F., Rombouts K., Böttcher K., Folseraas T., Weismüller T.J., Mason A.L., Wang W., Alexander G., Alvaro D., Bergquist A., Björkström N.K., Beuers U., Björnsson E., Boberg K.M., Bowlus C.L., Bragazzi M.C., Carbone M., Chazouillères O., Cheung A., Dalekos G., Eaton J., Eksteen B., Ellinghaus D., Färkkilä M., Festen E.A.M., Floreani A., Franceschet I., Gotthardt D.N., Hirschfield G.M., Hoek B.V., Holm K., Hohenester S., Hov J.R., Imhann F., Invernizzi P., Juran B.D., Lenzen H., Lieb W., Liu J.Z., Marschall H.-U., Marzioni M., Melum E., Milkiewicz P., Pares A., Rupp C., Rust C., Sandford R.N., Schramm C., Schreiber S., Schrumpf E., Silverberg M.S., Srivastava B., Sterneck M., Teufel A., Vallier L., Verheij J., Vila A.V., De Vries B., Zachou K., Chapman R.W., Manns M.P., Pinzani M., Rushbrook S.M., Lazaridis K.N., Franke A., Anderson C.A., Karlsen T.H., Ponsioen C.Y., Weersma R.K. (2018)
      Objective Primary sclerosing cholangitis (PSC) is a genetically complex, inflammatory bile duct disease of largely unknown aetiology often leading to liver transplantation or death. Little is known about the genetic ...

    • The hard way from bench to bedside history lessons from the pathogenesis of idiopathic membranous nephropathy (mn) 

      Stefanidis I., Nikolaou E., Karasavvidou F., Eleftheriadis T., Diamandopoulos A. (2020)
      Membranous nephropathy (MN) is one of the most common causes of adult nephrotic syndrome. Histopathology involves typical subepithelial immuncomplexes, with an obvious pathogenetic role. Today, the study of pathogenesis, ...

    • Regulatory B and T lymphocytes in multiple sclerosis: friends or foes? 

      Vasileiadis G.K., Dardiotis E., Mavropoulos A., Tsouris Z., Tsimourtou V., Bogdanos D.P., Sakkas L.I., Hadjigeorgiou G.M. (2018)
      Current clinical experience with immunomodulatory agents and monoclonal antibodies in principle has established the benefit of depleting lymphocytic populations in relapsing–remitting multiple sclerosis (RRMS). B and T ...